Level of CD30 expression, when assessed as above or below the median for the subtype, found no apparent correlation with likelihood of CR for patients with either AITL or PTCL-NOS (Supplementary Table S1, available at https://doi.org/10.1016/j.annonc.2021.12.002) and responses were observed across the range of CD30 expression (Supplementary Figure S2B and C, available at https://doi.org/10.1016/j.annonc.2021.12.002). This evidence concerns the gene TNFRSF8 and angioimmunoblastic T-cell lymphoma.